We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Kymera Therapeutics Poised for a Breakthrough With KT-621?
Read MoreHide Full Article
Key Takeaways
Kymera Therapeutics completed KT-621 phase IIb AD enrollment early, with pivotal data expected by 2026.
KYMR reported positive early KT-621 data and holds FDA Fast Track status in AD and eosinophilic asthma.
KYMR shares have outpaced the industry this year, while valuation remains above industry averages.
Kymera Therapeutics (KYMR - Free Report) is leveraging targeted protein degradation (TPD), a next-generation small-molecule therapeutic modality that harnesses the body's natural cellular recycling system to selectively eliminate disease-causing proteins.
The company is developing lead candidate KT-621, an oral STAT6 degrader, for inflammatory diseases such as atopic dermatitis (AD) and asthma.
The company recently completed enrollment in its phase IIb BROADEN2 study on KT-621 for the treatment of moderate-to-severe AD, about six months ahead of schedule. This means investors may see pivotal efficacy data by the end of 2026 instead of waiting until 2027, pulling forward a major catalyst.
Pending regulatory discussions, the company plans to begin phase III studies in AD by mid-2027.
In January 2026, Kymera expanded the BROADEN2 study to include adolescents alongside adults.
Kymera had earlier reported positive data from the phase Ib BroADen study of KT-621 in AD. The data was presented in a late-breaking oral session at the American Academy of Dermatology Annual Meeting. The findings demonstrated robust STAT6 degradation, reductions in type 2 inflammatory biomarkers, encouraging clinical activity, and a favorable safety profile, supporting STAT6 degradation as a novel oral therapeutic approach for type 2 inflammatory diseases.
Positive data highlight the candidate’s potential as an effective oral alternative to injectable biologics.
KT-621 is also being investigated in the ongoing phase IIb BREADTH trial in moderate-to-severe eosinophilic asthma, with data anticipated in late 2027.
The candidate has received Fast Track designation from the FDA for the treatment of moderate-to-severe AD and eosinophilic asthma.
The successful development of the candidate will be a significant boost for the company.
Competition for KYMR’s in Protein Degrader Therapies
Arvinas (ARVN - Free Report) is a clinical-stage biotechnology company pioneering PROTAC (PROteolysis TArgeting Chimera) protein degradation therapies.
ARVN, in partnership with Pfizer, developed Veppanu (vepdegestrant), the first FDA-approved PROTAC therapy, for adults with ER-positive/HER2-negative, ESR1-mutated advanced or metastatic breast cancer whose disease has progressed after at least one line of endocrine therapy.
Arvinas is advancing a diversified pipeline of investigational therapies, including ARV-102 for neurodegenerative disorders, ARV-806 for KRAS G12D-mutated cancers such as pancreatic and colorectal cancer, ARV-393 for relapsed/refractory non-Hodgkin lymphoma, ARV-027 for spinal-bulbar muscular atrophy (Kennedy's disease), and vepdegestrant for patients with locally advanced or metastatic ER-positive/HER2-negative breast cancer.
Nurix Therapeutics (NRIX - Free Report) , a clinical-stage biopharmaceutical company, is also developing targeted protein degradation therapies for cancer and autoimmune diseases. Nurix's clinical pipeline includes bexobrutideg, a BTK degrader being co-developed with Roche for oncology and autoimmune indications; NX-1607, a CBL-B inhibitor for cancer; and an IRAK4 degrader partnered with Gilead for autoimmune diseases.
NRIX is also advancing a portfolio of preclinical protein degraders and degrader-antibody conjugates, supported by strategic collaborations with Roche, Gilead, Sanofi and Pfizer.
KYMR’s Price, Valuation and Estimates
Shares of the company have gained 41.9% year to date compared with the industry’s growth of 2%.
Image Source: Zacks Investment Research
Going by the price/book ratio, KYMR’s shares currently trade at 5.90X, higher than its mean of 3.57X and the industry’s 3.49X.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 loss per share has narrowed to $3.28 from $3.30 over the past 60 days, while that for 2027 loss has widened to $4.23 from $4.19 in the same time frame.
View the Zacks #1 Rank List
Image: Bigstock
Is Kymera Therapeutics Poised for a Breakthrough With KT-621?
Key Takeaways
Kymera Therapeutics (KYMR - Free Report) is leveraging targeted protein degradation (TPD), a next-generation small-molecule therapeutic modality that harnesses the body's natural cellular recycling system to selectively eliminate disease-causing proteins.
The company is developing lead candidate KT-621, an oral STAT6 degrader, for inflammatory diseases such as atopic dermatitis (AD) and asthma.
The company recently completed enrollment in its phase IIb BROADEN2 study on KT-621 for the treatment of moderate-to-severe AD, about six months ahead of schedule. This means investors may see pivotal efficacy data by the end of 2026 instead of waiting until 2027, pulling forward a major catalyst.
Pending regulatory discussions, the company plans to begin phase III studies in AD by mid-2027.
In January 2026, Kymera expanded the BROADEN2 study to include adolescents alongside adults.
Kymera had earlier reported positive data from the phase Ib BroADen study of KT-621 in AD. The data was presented in a late-breaking oral session at the American Academy of Dermatology Annual Meeting. The findings demonstrated robust STAT6 degradation, reductions in type 2 inflammatory biomarkers, encouraging clinical activity, and a favorable safety profile, supporting STAT6 degradation as a novel oral therapeutic approach for type 2 inflammatory diseases.
Positive data highlight the candidate’s potential as an effective oral alternative to injectable biologics.
KT-621 is also being investigated in the ongoing phase IIb BREADTH trial in moderate-to-severe eosinophilic asthma, with data anticipated in late 2027.
The candidate has received Fast Track designation from the FDA for the treatment of moderate-to-severe AD and eosinophilic asthma.
The successful development of the candidate will be a significant boost for the company.
Competition for KYMR’s in Protein Degrader Therapies
Arvinas (ARVN - Free Report) is a clinical-stage biotechnology company pioneering PROTAC (PROteolysis TArgeting Chimera) protein degradation therapies.
ARVN, in partnership with Pfizer, developed Veppanu (vepdegestrant), the first FDA-approved PROTAC therapy, for adults with ER-positive/HER2-negative, ESR1-mutated advanced or metastatic breast cancer whose disease has progressed after at least one line of endocrine therapy.
Arvinas is advancing a diversified pipeline of investigational therapies, including ARV-102 for neurodegenerative disorders, ARV-806 for KRAS G12D-mutated cancers such as pancreatic and colorectal cancer, ARV-393 for relapsed/refractory non-Hodgkin lymphoma, ARV-027 for spinal-bulbar muscular atrophy (Kennedy's disease), and vepdegestrant for patients with locally advanced or metastatic ER-positive/HER2-negative breast cancer.
Nurix Therapeutics (NRIX - Free Report) , a clinical-stage biopharmaceutical company, is also developing targeted protein degradation therapies for cancer and autoimmune diseases. Nurix's clinical pipeline includes bexobrutideg, a BTK degrader being co-developed with Roche for oncology and autoimmune indications; NX-1607, a CBL-B inhibitor for cancer; and an IRAK4 degrader partnered with Gilead for autoimmune diseases.
NRIX is also advancing a portfolio of preclinical protein degraders and degrader-antibody conjugates, supported by strategic collaborations with Roche, Gilead, Sanofi and Pfizer.
KYMR’s Price, Valuation and Estimates
Shares of the company have gained 41.9% year to date compared with the industry’s growth of 2%.
Image Source: Zacks Investment Research
Going by the price/book ratio, KYMR’s shares currently trade at 5.90X, higher than its mean of 3.57X and the industry’s 3.49X.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 loss per share has narrowed to $3.28 from $3.30 over the past 60 days, while that for 2027 loss has widened to $4.23 from $4.19 in the same time frame.
Image Source: Zacks Investment Research
KYMR currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.